Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spruce Biosciences (SPRB) Change in Account Payables (2022 - 2025)

Spruce Biosciences (SPRB) has disclosed Change in Account Payables for 4 consecutive years, with -$443000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 12.1% to -$443000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$352000.0 through Dec 2025, up 82.72% year-over-year, with the annual reading at -$352000.0 for FY2025, 82.72% up from the prior year.
  • Change in Account Payables for Q4 2025 was -$443000.0 at Spruce Biosciences, down from $579000.0 in the prior quarter.
  • The five-year high for Change in Account Payables was $2.2 million in Q3 2023, with the low at -$2.5 million in Q2 2023.
  • Average Change in Account Payables over 4 years is -$117500.0, with a median of -$131500.0 recorded in 2023.
  • Peak annual rise in Change in Account Payables hit 217.97% in 2023, while the deepest fall reached 844.94% in 2023.
  • Over 4 years, Change in Account Payables stood at -$755000.0 in 2022, then skyrocketed by 123.84% to $180000.0 in 2023, then crashed by 380.0% to -$504000.0 in 2024, then increased by 12.1% to -$443000.0 in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$443000.0, $579000.0, and -$1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.